• 1
    Baer, M.R., Stewart, C.C., Lawrence, D., Arthur, D.C., Byrd, J.C., Davey, F.R., Schiffer, C.A. & Bloomfield, C.D. (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood, 90, 16431648.
  • 2
    Bloomfield, C.D., Lawrence, D., Arthur, D.C., Berg, D.T., Schiffer, C.A. & Mayer, R.J. (1994) Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group. Blood, 84, (Suppl. 1), abstract 111a.
  • 3
    Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A., Pettenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 41734179.
  • 4
    Byrd, J.C., Dodge, R.K., Carroll, A., Baer, M.R., Edwards, C., Stamberg, J., Qumsiyeh, M., Moore, J.O., Mayer, R.J., Schiffer, C.A. & Bloomfield, C.D. (1998) Patients with t(8;21)(q22;q22) and AML have a superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Blood, 92, (Suppl. 1), abstract 1282.
  • 5
    Byrd, J.C., Weiss, R.B., Arthur, D.C., Lawrence, D., Baer, M.R., Davey, F., Trikha, E.S., Carroll, A.J., Tantravahi, R., Qumsiyeh, M., Patil, S.R., Moore, J.O., Mayer, R.J., Schiffer, C.A. & Bloomfield, C.D. (1997) Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. Journal of Clinical Oncology, 15, 466475.
  • 6
    Campana, D., Coustan-Smith, E. & Janossy, G. (1990) The immunologic detection of minimal residual disease in acute leukemia. Blood, 76, 163171.
  • 7
    Macedo, A., Orfao, A., Gonzalez, M., Viridales, M.B., Lopez-Berges, M.C., Martinez, A. & San Miguel, J.F. (1995a) Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease. Leukemia, 9, 993998.
  • 8
    Macedo, A., Orfao, A., Viridales, M.B., Lopez-Berges, M.C., Valverde, B., Gonzalez, M., Caballero, M.D., Ramos, F., Martinez, M. & Fernandez-Calvo, J. (1995b) Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology, 70, 189194.DOI: 10.1007/s002770050054
  • 9
    Murray, C.K., Estey, E., Paietta, E., Howard, R.S., Edenfield, W.J., Pierce, S., Mann, K.P., Bolan, C. & Byrd, J.C. (1999) CD56 expression in APL: a possible indication of poor treatment outcome? Journal of Clinical Oncology, 17, 293297.
  • 10
    San Miguel, J.F., Martinez, A., Macedo, A., Viridales, M.B., Lopez-Berges, C., Gonzalez, M., Caballero, D., Diaz Mediavilla, J. & Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 24652670.